BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol 2015; 21(43): 12439-12447 [PMID: 26604651 DOI: 10.3748/wjg.v21.i43.12439] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Yang R, Xu Y, Hou W, Wang L, Xiao S, Li C, Shao H, Fei X, Wang Z. Transitional Care for Patients With Portal Hypertension: A Multicenter Study of Intervention for Post-TIPS Patients. Clin Nurs Res 2022;:10547738221112746. [PMID: 36047431 DOI: 10.1177/10547738221112746] [Reference Citation Analysis]
2 Yan J, Ying X, Malhotra A, Talenfeld A, Charalel R, Lee KS, Trost D, Kesselman A. Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt. Cardiovasc Intervent Radiol 2021. [PMID: 34859308 DOI: 10.1007/s00270-021-03012-y] [Reference Citation Analysis]
3 Lu HL, Xuan FF, Luo YC, Qin X. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt. Abdom Radiol (NY) 2021;46:5417-27. [PMID: 34302511 DOI: 10.1007/s00261-021-03214-5] [Reference Citation Analysis]
4 Cannataci C, Cimo' B, Mamone G, Tuzzolino F, D'Amico M, Cortis K, Maruzzelli L, Miraglia R. Portal vein puncture-related complications during transjugular intrahepatic portosystemic shunt creation: Colapinto needle set vs Rösch-Uchida needle set. Radiol Med 2021;126:1487-95. [PMID: 34405340 DOI: 10.1007/s11547-021-01404-1] [Reference Citation Analysis]
5 Shah KY, Gaba RC. Transjugular Intrahepatic Portosystemic Shunt Creation in Patients with Hepatocellular Carcinoma and Bleeding Gastric Varices: More Data, More Questions. J Vasc Interv Radiol 2021;32:971-3. [PMID: 34210483 DOI: 10.1016/j.jvir.2021.05.011] [Reference Citation Analysis]
6 Chen X, Qiu ZK, Wang GB, Chen XL, Zhang FJ, Gao F. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol 2021;27:671-6. [PMID: 34318755 DOI: 10.5152/dir.2021.20358] [Reference Citation Analysis]
7 Tsauo J, Noh SY, Shin JH, Gwon DI, Han K, Lee JM, Jeon UB, Kim YH. Retrograde transvenous obliteration for the prevention of variceal rebleeding in patients with hepatocellular carcinoma: a multicentre retrospective study. Clin Radiol 2021;76:681-7. [PMID: 34140137 DOI: 10.1016/j.crad.2021.05.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, Guo WH, Li X. Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of Gastric Variceal Rebleeding in Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Vasc Interv Radiol 2021;32:963-9. [PMID: 33864909 DOI: 10.1016/j.jvir.2021.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Luo J, Li M, Wu C, Zhu D, Wang H, Huang M, Jiang Z. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. Eur J Gastroenterol Hepatol 2021;33:436-42. [PMID: 32398493 DOI: 10.1097/MEG.0000000000001750] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ruohoniemi DM, Taslakian B, Aaltonen EA, Hickey R, Patel A, Horn JC, Chiarello M, Mcdermott M. Comparative Analysis of Safety and Efficacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology 2020;31:409-15. [DOI: 10.1016/j.jvir.2019.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Luo SH, Chu JG, Huang H, Yao KC. Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World J Clin Cases 2019; 7(13): 1599-1610 [PMID: 31367619 DOI: 10.12998/wjcc.v7.i13.1599] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhao H, Tsauo J, Zhang X, Gong T, Li J, Li X. Transjugular intrahepatic portosystemic shunt creation for portal hypertension in patients with hepatocellular carcinoma: A systematic review. Int J Gastrointest Interv 2018;7:167-71. [DOI: 10.18528/gii180026] [Reference Citation Analysis]
13 Zhang Y, Mao DF, Zhang MW, Fan XX. Clinical value of liver and spleen shear wave velocity in predicting the prognosis of patients with portal hypertension. World J Gastroenterol 2017; 23(45): 8044-8052 [PMID: 29259380 DOI: 10.3748/wjg.v23.i45.8044] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40:1372-1382. [PMID: 28488102 DOI: 10.1007/s00270-017-1655-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]